Immunologic Factor
Impact of New CDC Guidelines on RSV Vaccine Makers
RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations
FDA Approves Tecelra, the First Engineered Cell Therapy for Solid Tumors, to Treat Synovial Sarcoma
Tecelra, Adaptimmune, FDA approval, engineered cell therapy, solid tumor, synovial sarcoma, MAGE-A4 antigen, TCR cell therapy
FDA Approves Broader Label for GSK’s Jemperli in First-Line Endometrial Cancer
FDA, GSK, Jemperli, dostarlimab-gxly, endometrial cancer, chemotherapy, carboplatin, paclitaxel, mismatch repair proficient, microsatellite stable, overall survival, progression-free survival
Valneva Invests $10M in LimmaTech for Clinical-Stage Shigella Vaccine
Valneva, LimmaTech, Shigella vaccine, clinical-stage, biotech, pharmaceuticals, vaccine development
FDA Approves Johnson & Johnson’s New Multiple Myeloma Therapy
FDA approval, Johnson & Johnson, multiple myeloma, CAR-T cell therapy, bispecific antibody, TALVEY, CARVYKTI, DARALEXASPRO
Incyte Discontinues Five Early-Stage Oncology Programs in Pipeline Refocus
Incyte, cancer pipeline, oncology programs, PD-L1 inhibitors, strategic review, R&D refocus
FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials
FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca
GSK Abandons Phase 2 HPV Vaccine Due to Lack of Best-in-Class Potential
GSK, HPV vaccine, phase 2, best-in-class potential, vaccine development
FibroGen to Shrink US Workforce by 75% Following More Late-Stage Fails
FibroGen, workforce reduction, pamrevlumab, clinical trials, biotech layoffs, pancreatic cancer drug
BioNTech-Regeneron vs. Moderna-Merck.Cancer Vaccine and PD-1 Inhibitor Combinations.
, BioNTech, Regeneron, Moderna, Merck, Cancer Vaccine, PD-1 Inhibitor, mRNA Technology, Melanoma, Immunotherapy, Clinical Trials,